Mitsubishi UFJ Asset Management UK Ltd. Decreases Position in Gilead Sciences, Inc. $GILD

Mitsubishi UFJ Asset Management UK Ltd. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.1% during the fourth quarter, Holdings Channel reports. The firm owned 19,000 shares of the biopharmaceutical company’s stock after selling 9,000 shares during the quarter. Gilead Sciences comprises approximately 1.1% of Mitsubishi UFJ Asset Management UK Ltd.’s holdings, making the stock its 25th biggest position. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in Gilead Sciences were worth $2,332,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Gilead Sciences by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares in the last quarter. Invesco Ltd. boosted its position in Gilead Sciences by 12.0% during the third quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares in the last quarter. Legal & General Group Plc boosted its position in Gilead Sciences by 4.2% during the third quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after purchasing an additional 414,454 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Gilead Sciences by 5.9% during the third quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock worth $793,506,000 after purchasing an additional 400,002 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in Gilead Sciences by 16.5% during the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after purchasing an additional 726,101 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead was highlighted in a hedge-fund screen as one of the “best long-term low-risk stocks,” which may reinforce the view that institutional investors see it as a relatively defensive large-cap healthcare name. 5 Best Long Term Low Risk Stocks to Buy According to Hedge Funds
• Positive Sentiment: The company presented at the RBC Capital Markets Global Healthcare Conference, keeping investor focus on Gilead’s HIV, oncology, and pipeline outlook following its recent earnings beat. Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
• Positive Sentiment: Daiwa Securities lowered its price target to $150 from $161 but kept an Outperform rating, suggesting the firm still sees upside from current levels despite the cut.
• Positive Sentiment: Recent commentary around Gilead’s Q1 results pointed to solid execution, including strong HIV franchise performance and momentum in oncology, which supports the stock’s valuation. Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions
• Neutral Sentiment: Gilead’s CFO and another senior insider disclosed stock sales, but both were made under pre-arranged 10b5-1 plans, which limits the bearish signal. Gilead Sciences (NASDAQ:GILD) CFO Sells $396,810.00 in Stock
• Negative Sentiment: Despite the constructive backdrop, analyst target cuts and insider selling may be creating some caution and helping cap gains in the near term.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the transaction, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total value of $396,810.00. Following the transaction, the chief financial officer owned 173,191 shares in the company, valued at $22,907,973.57. This trade represents a 1.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 63,000 shares of company stock worth $8,523,570. 0.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on GILD shares. Citigroup upped their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. UBS Group upped their price objective on Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Wolfe Research upped their price objective on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Royal Bank Of Canada reduced their price objective on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating on the stock in a research report on Friday, May 8th. Finally, The Goldman Sachs Group upped their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, April 17th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $156.62.

Gilead Sciences Stock Up 0.6%

Shares of NASDAQ:GILD opened at $130.50 on Wednesday. The stock’s fifty day simple moving average is $137.18 and its 200-day simple moving average is $133.48. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The company has a market capitalization of $162.02 billion, a P/E ratio of 17.78 and a beta of 0.31. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the business posted $1.81 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post -0.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is 44.69%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.